Cardiac cell therapies for myocardial regeneration are shifting focus toward paracrine products and their integration with biocompatible materials to overcome current clinical limitations.
The future of cardiac cell therapy for myocardial infarction lies in utilizing isolated paracrine products combined with biocompatible materials for tissue engineering.
Myocardial infarction (MI), caused by coronary heart disease (CHD), remains one of the most common causes of death in the United States. Over the last few decades, scientists have invested considerable resources on the study and development of cell therapies for myocardial regeneration after MI. However, due to a number of limitations, they are not yet readily available for clinical applications. Mounting evidence supports the theory that paracrine products are the main contributors to the regenerative effects attributed to these cell therapies. The next generation of cell-based MI therapies will identify and isolate cell products and derivatives, integrate them with biocompatible materials and technologies, and use them for the regeneration of damaged myocardial tissue. This review discusses the progress made thus far in pursuit of this new generation of cell therapies. Their fundamental regenerative mechanisms, their potential to combine with other therapeutic products, and their role in shaping new clinical approaches for heart tissue engineering, are addressed.
Huang et al. (Thu,) conducted a review in Myocardial infarction. Cardiac cell therapy was evaluated. Cardiac cell therapies for myocardial regeneration are shifting focus toward paracrine products and their integration with biocompatible materials to overcome current clinical limitations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: